The early detection of sepsis is vital in order to provide an appropriate patient treatment plan. Here, Wayne Kipp provides an overview of the condition and looks at the merits of the latest procalcitonin assay.
www.en.wikipedia.org Jmol Development Team Public domain
According to the Global Sepsis Alliance, sepsis affects over 26 million people each year and is the largest killer of children and newborns worldwide. Despite advances in knowledge, sepsis continues to increase at an annual rate of 8-13%, calling for a greater improvement in both the diagnosis and treatment of severe bacterial infections.
Procalcitonin (PCT) is a useful marker for bacterial infection and therefore sepsis, and proves beneficial in determining whether a patient is suffering from a bacterial or viral infection. This distinction is useful in deciding between treatment options and helps to ensure that antibiotics are only given when a bacterial infection is indicated.
Recent advances in the accuracy, speed and accessibility of PCT tests will help to improve the chances of identifying sepsis early in order to direct the correct course of treatment. For example, the Stanbio PCT LiquiColor assay (EKF Diagnostics, Cardiff) incorporates a methodology that provides quick and accurate results, as well as a cost-effective implementation that does not require dedicated instrumentation.
Log in or register FREE to read the rest
This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text.
If you don't already have an account, please register with us completely free of charge.